Bilaga 4 - Klassifikation av MDS enligt WHO 5th edition och International Consensus Classification (ICC)

Myelodysplastiskt syndrom (MDS)

MDS with defining genetic abnormalities

•        MDS with low blasts and isolated 5q deletion (MDS-5q)

•        MDS with low blasts and SF3B1 mut (MDS-SF3B1)

•        MDS with biallelic TP53 inactivation (MDS-biTP53)

MDS morphologically defined

•        MDS with low blasts (MDS-LB) (< 5 % BM, < 2 % PB)

•        MDS, hypoplastic (MDS-h)

•        MDS with increased blasts (MDS-IB)

•      MDS-IB1 (5–9 % BM or 2–4 % PB)

•      MDS-IB2 (10–19 % BM or 5–19 % PB or Auer rods)

•      MDS with fibrosis (5–19 % BM or 2–19 % PB)

Childhood myelodysplastic neoplasms (MDS)

•        With low blasts (< 5 % BM, < 2 % PB)

•        With increased blasts (5–9 % BM or 2–19 % PB)

Myelodysplastiskt syndrom (MDS)

•        MDS with mutated SF3B1 

•        MDS with del(5q) 

•        MDS with mutated TP53 

MDS, not otherwise specified (MDS, NOS) 

•        MDS, NOS without dysplasia 

•        MDS, NOS with single lineage dysplasia 

•        MDS, NOS with multilineage dysplasia

•        MDS with fibrosis (5–19 % BM or 2–19 % PB)

Myelodysplastic syndrome with excess blasts (MDS-EB)

•        With low blasts (< 5 % BM, < 2 % PB)

•        With increased blasts (5–9 % BM, or 2–19 % PB)

Myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) 

•        MDS/AML with mutated TP53 

•        MDS/AML with myelodysplasia-related gene mutations 

•        MDS/AML with myelodysplasia-related cytogenetic abnormalities 

•        MDS/AML, myelodysplastic/myeloproliferative neoplasm, unclassifiable